Johnson & Johnson (NYSE:JNJ) says it will work with Emergent BioSolutions (NYSE:EBS) to produce more than a billion doses of a COVID-19 vaccine candidate, as it seeks to scale up global manufacturing of its potential treatment.
J&J says it is already preparing for clinical
vaccine production at its Leiden facility in the Netherlands, with the
aim of starting its Phase 1 clinical trial of its vaccine candidate on
humans in September and potentially having it ready under an emergency
use authorization next year.
Emergent, which says it values the deal at ~$135M,
will provide drug substance manufacturing services and is reserving
large-scale capacity to pave the way for commercial manufacturing of the
vaccine beginning in 2021.
J&J says it will start production “at risk and
is committed to bringing an affordable vaccine to the public on a
not-for-profit basis.”
https://seekingalpha.com/news/3564016-j-and-j-to-partner-emergent-bio-on-coronavirus-vaccine-candidate
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.